Transplantation for bone marrow failure: current issues

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Idiopathic aplastic anemia (AA) treatment primarily involves allogeneic hematopoietic stem cell transplantation (HSCT).
• Alternative donor sources and strategies are crucial for patients lacking HLA-identical sibling donors.
• HSCT also addresses congenital disorders with cytopenias.

Purpose of the Study:

• To summarize recent advancements in HSCT for idiopathic and inherited AA.
• To discuss the impact of age, paroxysmal nocturnal hemoglobinuria, and GVHD prevention on HSCT outcomes.
• To examine emerging strategies for upfront unrelated donor and alternative donor HSCT in AA.

Main Methods:

• Review of recent literature on HSCT for aplastic anemia and related disorders.
• Analysis of outcomes based on donor type (sibling, unrelated, alternative) and patient factors (age).
• Discussion of strategies for GVHD prevention and management of clonal evolution.

Main Results:

• HSCT outcomes are influenced by donor type, patient age, and GVHD prophylaxis.
• Advances in unrelated donor and alternative donor HSCT expand treatment options for AA.
• Improved GVHD prevention strategies enhance long-term quality of life post-transplant.

Conclusions:

• HSCT remains a primary curative option for AA, with evolving donor strategies.
• Minimizing long-term complications like chronic GVHD is essential for patient well-being.
• Ongoing research focuses on optimizing HSCT for diverse patient populations and inherited bone marrow failure syndromes.